



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/537,630	06/03/2005	Louis-David Cantin	5150	4617
35969 7590 03/17/2008 Bayer Health Care LLC 400 Morgan Lane West Haven, CT 06516				
EXAMINER ANDERSON, REBECCA L				
ART UNIT		PAPER NUMBER		
1626				
MAIL DATE		DELIVERY MODE		
03/17/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/537,630

Applicant(s)

CANTIN ET AL.

Examiner

REBECCA L. ANDERSON

Art Unit

1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-40 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-40 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SF/86)
Paper No(s)/Mail Date ____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date ____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: ____

DETAILED ACTION

Claims 1-40 are currently pending in the instant application and are subject to a lack of unity requirement.

Election/Restrictions


Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. Due to the numerous and widely divergent subject matter claimed, a precise listing of inventive groups cannot be made. The following groups are exemplary:

Group I, Claims 1-13, 27, 28 and 40 drawn to products of the formula (I) wherein L is $-(CH_2)_m-X-$ and Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R₃ groups.

Group II, Claims 1-13, 27, 28 and 40 drawn to products of the formula (I) wherein L is $Y-(CH_2)_m-X-$ and Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R₃ groups and fused to a furan ring wherein said furan ring may be optionally substituted at any available position by 1 to 4 independently selected R₄ groups.

Group III, Claims 1-13, 27, 28 and 40 drawn to products of the formula (I) wherein L is



and Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R₃ groups and fused to a pyrrole ring wherein said pyrrole


Art Unit: 1626

ring may be optionally substituted at any available position by 1 to 4 independently selected R4 groups.

Group IV, Claims 1-13, 27, 28 and 40 drawn to products of the formula (I) wherein L is - (CH₂)_m-X- and Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R3 groups and fused to a thiazole ring wherein said thiazole ring may be optionally substituted at any available position by 1 to 4 independently selected R4 groups.

Group V, Claims 1-13, 27, 28 and 40 drawn to products of the formula (I) wherein L is - Y-(CH₂)_m-X- and Ar is pyridyl optionally substituted at any available position by 1 to 5 independently selected R3 groups.

Group VI, Claims 1-13, 27, 28 and 40 drawn to products of the formula (I) wherein L is



and Ar is pyrimidyl optionally substituted at any available


position by 1 to 5 independently selected R3 groups.

Group VII, Claims 1-13, 27, 28 and 40 drawn to products of the formula (I) wherein L is -(CH₂)_m-X- and Ar is pyridazinyl optionally substituted at any available position by 1 to 5 independently selected R3 groups.

Group VIII, Claims 1-13, 27, 28 and 40 drawn to products of the formula (I) wherein L is -Y-(CH₂)_m-X- and Ar is pyrazinyl optionally substituted at any available position by 1 to 5 independently selected R3 groups.

Art Unit: 1626

Group IX, Claims 1-13, 27, 28 and 40 drawn to products of the formula (I) wherein L is




and Ar is triazinyl optionally substituted at any available position

by 1 to 5 independently selected R3 groups.

Group X, Claims 14-36 drawn to methods of treatment with products of the formula (I) wherein L is $\text{---}(\text{CH}_2)_m\text{---X---}$ and Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R3 groups and fused to a thiazole ring wherein said thiazole ring may be optionally substituted at any available position by 1 to 4 independently selected R4 groups.

Group XI, Claims 14-36 drawn to methods of treatment with products of the formula (I) wherein L is $\text{---Y---}(\text{CH}_2)_m\text{---X---}$ and Ar is pyridyl optionally substituted at any available position by 1 to 5 independently selected R3 groups.

Group XII, Claims 14-36 drawn to methods of treatment with products of the formula (I)




wherein L is and Ar is pyrimidyl optionally substituted at any available position by 1 to 5 independently selected R3 groups.

Group XIII, Claims 14-36 drawn to methods of treatment with products of the formula (I) wherein L is $\text{---}(\text{CH}_2)_m\text{---X---}$ and Ar is pyridazinyl optionally substituted at any available position by 1 to 5 independently selected R3 groups.

Art Unit: 1626

Group XIV, Claim 39 drawn to a process for the preparation of a medicament of the formula (I) wherein L is $-Y-(CH_2)_m-X-$ and Ar is pyrazinyl optionally substituted at any available position by 1 to 5 independently selected R3 groups.

Group XV, Claim 39 drawn to a process for the preparation of a medicament of the



formula (I) wherein L is

and Ar is triazinyl optionally substituted at

any available position by 1 to 5 independently selected R3 groups.

(Note: Claim 39 is an improper "use" claim under 35 USC 101 and has been interpreted as a method of preparing a medicament.)

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.


Again, this list is not exhaustive as it would be impossible under the time constraints due to the sheer volume of subject matter instantly claimed. Therefore, applicant may choose to elect a single invention (a product, a process of preparation, or a method of use) by identifying another specific embodiment of similar scope to the exemplary groups which is not listed in the exemplary groups of the invention and examiner will endeavor to group the same. The applicant may also choose to elect a single disclosed species or a single disclosed species for a single method or single process and the examiner will endeavor to create a group comprising the elected species of similar scope to the exemplary groups.

The claims herein lack unity of invention under PCT rule 13.1 and 13.2 since, under 37 CFR 1.475(a):

Art Unit: 1626

Where a group of inventions is claimed in an application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features...those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

Groups I-XV lack unity of invention since under 37 CFR 1.475: the technical



feature corresponding to the claims is:

. This technical feature is

not a special technical feature because it fails to define a contribution over the prior art as can be seen, for example, by WO 03/011842, which discloses the compounds of formula (I) and (III). Therefore claims 1-40 are not so linked as to form a single general inventive concept and there is a lack of unity of invention because they lack a special technical feature as the technical feature present fails to define a contribution over the prior art. Additionally, the variables found on the technical feature vary extensively and when taken as a whole result in vastly different compounds. Accordingly, unity of invention is considered to be lacking and restriction of the invention in accordance with the rules of unity of invention is considered to be proper. Additionally, the vastness of the claimed subject matter, and the complications in understanding the claimed subject matter impose a serious burden on any examination of the claimed subject matter.

Therefore, since the claims do not relate to a single general inventive concept under PCT Rule 13.1 and lack the same or corresponding special technical feature, the claims lack unity of invention and should be limited to only a product, a process of preparation or a method of use.

Furthermore, in regards to groups I-XV even if unity of invention under 37 CFR 1.475(a) is not considered lacking, which it is, under 37 CFR 1.475(b) a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations:

- (1) A product and a process specially adapted for the manufacture of said product;
or
- (2) A product and a process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) A process and an apparatus or means specifically designed for carrying out the said process; or
- (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.

And, according to 37 CFR 1.475(c)

if an application contains claims to more or less than one of the combinations of categories of invention set forth in paragraph (b), unity of invention might not be present.

Therefore, since the claims are drawn to more than a product, a process of use and a process of preparation, and according to 37 CFR 1.475 (e)

the determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim.

The claims, therefore, lack unity of invention.

Conclusion

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rebecca L. Anderson whose telephone number is (571) 272-0696. Mrs. Anderson can normally be reached Monday through Friday from 6:00am until 2:30pm.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Mr. Joseph K. McKane, can be reached at (571) 272-0699.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Rebecca Anderson/
Primary Examiner, AU 1626

10 March 2008

Rebecca Anderson
Primary Examiner
Art Unit 1626, Group 1620
Technology Center 1600